Airway Responses to Montelukast and Desloratadine.

University of Saskatchewan12 enrolled

Overview

Montelukast (for asthma) and desloratadine (for allergies) are effective therapy for their current uses. Part of what happens when your allergies trigger your asthma should be prevented by either of these drugs. This project is being conducted to determine if these drugs are effective, either alone or in combination, on controlling asthma that is triggered by allergies.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Asthma

Interventions

Montelukast (10mg) and Desloratadine (5mg)DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * baseline FEV1 \> or = 65% predicted * positive methacholine challenge (i.e. methacholine PC20 \< or = 16mg/ml * positive allergen challenge Exclusion Criteria: * negative skin prick test * lung condition/disease other than asthma * currently use montelukast and/or desloratadine

Locations (1)

Room 346 Ellis Hall

Saskatoon, Saskatchewan, Canada

Outcomes

Primary Outcomes

Late asthmatic response (maximum percent decrease in FEV1)

Secondary Outcomes

Early asthmatic response (maximum percent decrease in FEV1

Changes in sputum cell/mediator content

Changes in airway hyperresponsiveness (methacholine PC20)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.